Pulmonology

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The therapy is currently approved in almost 50 countries under the name Trimbow.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Explore how healthcare resilience and sustainability intertwine, addressing climate challenges while enhancing patient care and community health outcomes.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.